J O H N S O N
PHARMACARE LIMITED

CIN: L51100GJ1994PLC022388
Registered & Corp. Office Address - I-460, Fourth Floor,
Titanium City Centre Mall, Near Sachin Tower,
Anand Nagar Road, Satellite, Ahmedabad-380015

Email id: johnsonpharmacare1994@gmail.com
sunandshineworldwideltd@gmail.com

Date: 13th August, 2026

To,
The Department of Corporate Service
BSE Limited
PhirozeJeejeebhoy Towers,
Dalal Street, Mumbai – 400001.

SCRIP CODE: 532154 (JOHNSON PHARMACARE LTD)
EQ - ISIN - INE560F01022

Subject: Outcome of Meeting of Board of Directors held on Thursday, 13th August, 2026 at pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

Pursuant to the provisions of Regulation 30 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the meeting of the Board of Directors of the Company was held today i.e., **Thursday 13th August, 2026** which commenced at **05:00 P.M**. and concluded at **05:30 P.M.** at the registered office of the company at **- I-460, Fourth Floor, Titanium City Centre Mall, Near Sachin Tower, Anand Nagar Road, Satellite, Ahmedabad-380015** have considered and approved the following:

1. **UN-AUDITED FINANCIAL RESULTS**

The Board of Director have considered and approved the Un-Audited Financial Results along with Limited Review Report thereon for quarter ended on June 30th, 2026. In this regard, please find enclosed herewith the Un-Audited Financial Results along with Limited Review Report for the quarter ended on June 30th, 2026 pursuant to the Regulation 33 of SEBI (LODR) Regulations, 2015.

The copy of the said Un-Audited quarterly financial results along with copy of Limited Review Report by Statutory auditor of the company is enclosed herewith.

2. **STATEMENT OF DEVIATION OR VARIATION UNDER REGULATION 32 OF SEBI (LODR) REGULATIONS, 2015**

The Board discussed the compliance of Regulation 32 of SEBI (LODR) Regulations, 2015 and is of the view that the same is not applicable to company as the company has not issued equity share by way of Preferential Issue. The undertaking of Non-Applicability of Regulation 32 of SEBI (LODR) Regulations, 2015 for the quarter ended on June 30th, 2026 is enclosed herewith is enclosed herewith.

We request you to take the above information on record.

Thanking You,

Yours Faithfully,
For and on behalf of Board of Directors of
JOHNSON PHARMACARE LIMITED

NAND
KISHOR
RAY

Nand Kishor Ray
Additional Director
DIN: 11626638

Date: 13-08-2026
Place: Gujrat

JOHNSON PHARMACARE LIMITED

CIN: L51100GJ1994PLC022388

Registered Office -No.4-D, 4th Floor Vardan Tower, Lakhudi Circle, Near Sardar Patel Stadium Navrangpura, Ahmadabad City, Gujarat, India, 380009

Email id: sunandshineworldwideltd@gmail.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2026 - IND-AS COMPLIANT (NON NBFC)

(in Lakhs)

	Particulars	Three Months Ended			Year Ended
		CURRENT QUARTER	PREVIOUS QUARTER	CORRESPONDING QUARTER	YEAR TO DATE
		01.04.2026 to 30.06.2026	01.01.2026 to 31.03.2026	01.04.2025 to 30.06.2025	01.04.2025 to 31.03.2026
		unaudited	Audited	unaudited	Audited
	Income:				
I	Revenue from opertaions	-	-	-	-
II	Other income	-	158.10	-	158.10
III	**Total Income**	-	**158.10**	-	**158.10**
IV	**Expenses**				
	Cost of Materials consumed	-	-		-
	Purchase of stock-in-trade	-	-		-
	Changes in inventories of finished goods	-	-		-
	Change in inventories of finished goods, work-in-progress and Stock-in-Trade	-	-		-
	Employee benefits expense	0.50	1.00	0.30	1.81
	Finance costs	106.17	21.92	-	26.20
	Depreciation and amortisation expense	-	-	-	-
	Other expenses	3.64	4,269.24	5.04	4,276.48
	Total expenses	**110.31**	**4,292.16**	**5.34**	**4,304.49**
V	Profit/(loss) before exceptional items and tax (I- IV)	**(110.31)**	**(4,134.06)**	**(5.34)**	**(4,146.39)**
VI	**Exceptional Items**	-	1,427.00		1,427.00
VII	**Profit/(loss) before extraordinary items and tax(V-VI)**	**(110.31)**	**(5,561.06)**	**(5.34)**	**(5,573.39)**
VIII	**Extra ordinary item**	-	-		-
IX	**Profit Before Tax (VII-VIII)**	(110.31)	(5,561.06)	(5.34)	(5,573.39)
X	**Tax expense:**				
	(1) Current tax	-	-		-
	(2) Deferred tax	-	-		-
	(3) Excess Provision of earlier Year	-	-		-
	Total tax expenses		-		-
XI	**Profit (Loss) for the period from continuing operations (VII-VIII)**	**(110.31)**	**(5,561.06)**	**(5.34)**	**(5,573.39)**
XII	**Profit/(loss) from discontinued operations**	-	-		-
XIII	**Tax expense of discontinued operations**	-	-		-
XIV	**Profit/(loss) from Discontinued operations (after tax) (XII-XIII)**	-	-		-
XV	**Profit/(loss) for the period (XI+XIV)**	**(110.31)**	**(5,561.06)**	**(5.34)**	**(5,573.39)**
XVI	**Other Comprehensive Income**				
	A (i) Items that will not be reclassified to profit or loss	-	-		-
	(ii) Income tax relating to items that will not be re- classified to profit or loss	-	-		-
	B (i) Items that will be reclassified to profit or loss	-	-		-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-		-
XV	**Total Comprehensive Income for the period (XV+XVI)(Comprising Profit (Loss) and Other Comprehensive Income for the period)**	**(110.31)**	**(5,561.06)**	**(5.34)**	**(5,573.39)**
XVI	**Paid up equity share capital (Face value Rs. 1/- per share)**	5,500.00	5,500.00	5,500.00	5,500.00
XVII	**Earnings per equity share (for continuing operation):**				
	(1) Basic	(0.02)	(1.01)	(0.00)	(1.01)
	(2) Diluted	(0.02)	(1.01)	(0.00)	(1.01)
XVIII	**Earnings per equity share (for discontinued operation):**				
	(1) Basic	-	-		-
	(2) Diluted	-	-		-
	See accompanying note to the financial results				

For Johnson Pharmacare Limited

धीरज कुमार

Director/Auth. Signatory

Notes :

1 The above unudited financial results for the quarter 30th June 2026 has been reviewed by the Audit Committee and then approved by the Board of Directors at their meeting held on 13.08.2026.

2 The above results have been prepared in compliance with the recognition and measurement principles of the Companies (India Accounting Standards) Rules, 2015 as amended by the Companies (Indian Accounting Standards Amendment Rules, 2016) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable, begining 1st April, 2017, the company has for the first time adopted Ind AS with a transition date of 1st April, 2016.

3 The format for above results as prescribed in SEBI's circular CIR/SFD/CMS/15/2015 dated 30th November, 2015 has been modified to comply with requirements of SEBI's circular dated 5th July, 2016, Ind AS and Schedule III (Division-II) to the companies Act, 2013 applicable to companies that are required to comply with Ind AS.

4 The Limited review report have carried out on the above results for quarter ended 30th jUNE 2026 . However, the management has excercised necessary due diligence to ensure that the financial results provided true and fair view of its affairs.

5 Figures for the previous peried have been regrouped wherever considered necessary so as to confirm to the classification of the current period.

For and on behalf of board of directors of
JOHNSON PHARMACARE LIMITED
For Johnson Pharmacare Limited

धीरज कुमार

DHEERAJ KUMAR
Director/Auth. Signatory
Director
DIN: 11666616

Date: 13-08-2026
Place: New Delhi

JOHNSON PHARMACARE LIMITED

CIN: L51100GJ1994PLC022388
Registered Office-No. 4-D, 4th Floor Vardan Tower, Lakhudi Circle Near Sardar Patel Stadium NavrangpuraAhmadabad City Gujarat India- 380009
Email id: sunandshineworldwideltd@gmail.com

Unaudited Financial Result for the Quarter Ended 30th June 2026

(IN LACS EXCEPT EPS)

S.N	Particulars	Quarter Ended			Year Ended
		01.04.2026 to 30.06.2026	01.01.2026 to 31.03.2026	01.04.2025 to 30.06.2025	01.04.2025 to 31.03.2026
		Unaudited	Audited	Unaudited	Audited
1	Total Income from operation	-	158.10	-	158.10
2	Net Profit / Loss for the period before tax and exception items	(110.31)	(4,134.06)	(5.34)	(4,146.39)
3	Net Profit/ Loss for the period before tax (after exception itmes)	(110.31)	(5,561.06)	(5.34)	(5,573.39)
4	Net Profit/ Loss for the period after tax (after exception itmes)	(110.31)	(5,561.06)	(5.34)	(5,573.39)
5	Total [Comprehensive income/ loss for the period [comprising profit/ loss for the period (after tax) and other comprehensive income/ loss (after tax)]	(110.31)	(5,561.06)	(5.34)	(5,573.39)
6	Paid up equity share capital	5,500.00	5,500.00	5,500.00	5,500.00
7	Earning per share after exception item Basic & Diluted	(0.02)	(1.01)	(0.00)	(1.01)

Note 1. The above unaudited financial results for the quarter ended June 30th 2026 were reviewed by the Audit Committee at the meeting and approved by the Board of Directors and taken on record at the meeting held on 13.08.2026

2.The above is an extract of the detailed format of quarterly financial result filed with the stock exchange under Regulation 33 of the SEBI (Listing obligations and disclosure requirements) Regulations 2015.

For and on behalf of board of directors of
JOHNSON PHARMACARE LIMITED
For Johnson Pharmacare Limited
धीरज कुमार
Director/Auth. Signatory
DHEERAJ KUMAR
Director
DIN: 11666616

Date:13.08.2026
Place: New Delhi

Limited Review Report

Review report to Board of Directors of
JOHNSON PHARMACARE LIMITED

LIMITED REVIEW REPORT ON UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED ON JUNE 30TH, 2026 OF JOHNSON PHARMACARE LIMITED.

We have reviewed the accompanying statement of unaudited Standalone Financial Results of JOHNSON PHARMACARE LIMITED for the quarter ended 30.06.2026. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of Companies (India Accounting Standards) Rules, 2015 and the circular is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of any material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, subject to the matter given in Emphasis of matter we are of the opinion that the accompanying statement of unaudited standalone financial results, which have not been prepared in accordance with applicable accounting standards i.e. IND AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder. However, nothing has come to our attention which causes us to believe that the accompanying statement of unaudited standalone financial results do not disclosed the information required to be disclosed ins terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated 05th July, 2016, or by the Institute of Chartered Accountants of India and other recognized accounting practices and policies including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **VRSK & ASSOCIATES** *(Firm's Registration No. 011199N)*
Chartered Accountants

VRSK & ASSOCIATES
New Delhi
Chartered Accountants

Vineet

CA VINEET GUPTA *(Membership No.089823)*
Partner
New Delhi, August 13, 2026
UDIN: 26089823QIJLIK3495

J O H N S O N
PHARMACARE LIMITED

CIN: L51100GJ1994PLC022388
Registered & Corp. Office Address - I-460, Fourth Floor,
Titanium City Centre Mall, Near Sachin Tower,
Anand Nagar Road, Satellite, Ahmedabad-380015

Email id: johnsonpharmacare1994@gmail.com
sunandshineworldwideltd@gmail.com

Date: 13.08.2026

To,
The Department of Corporate ServiÎ
BSE Limited
PhirozeJeejeebhoy Towers,
Dalal Street, Mumbai – 400001.

SCRIP CODE: 532154 (JOHNSON PHARMACARE LTD)
EQ - ISIN - INE560F01022

Subject: Undertaking for Non- Applicability of Regulation 32 of SEBI (LODR) Regulations, 2015 for the quarter ended on June 30th, 2026.

Dear Sir/Madam,

As per Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the listed entity shall submit to the stock exchange the following statement(s) for quarter ended on June 30th, 2026 for public issue, rights issue, preferential issue etc. –

(a) Indicating deviations, if any, in the use of proceeds from the objects stated in the offer document or explanatory statement to the notice for the general meeting, as applicable;

(b) Indicating category wise variation (capital expenditure, sales and marketing, working capital etc.) between projected utilization of funds made by it in its offer document or explanatory statement to the notice for the general meeting, as applicable and the actual utilization of funds.

In view of the aforesaid, I, the undersigned, **Mr. NAND KISHOR RAY**, **Director** of **JOHNSON PHARMACARE LTD** hereby certify that Compliances of Regulation 32 of SEBI (LODR) regulations, 2015 is **not applicable** to the company as the company **has not issued** any share by way of public issue, right issue, preferential issue etc. for the quarter ended on June 30th, 2026.

You are requested to take the above on your records and acknowledge the same.

For and on behalf of Board of Directors
JOHNSON PHARMACARE LIMITED

NAND
KISHOR
RAY

Digitally signed by NAND KISHOR RAY
DN: c=IN, o=Personal, title=5058,
2.5.4.20=4ab370811dbebb2922c659e3
8869ccfa0f6700d48feeee8c8930227ea5
03fd72, postalCode=843103, st=Bihar,
serialNumber=85d5d23d4549c2796faf9
31df7f154c0554c210d614a91adb5688a
d7a635ae6c, cn=NAND KISHOR RAY
Date: 2026.08.13 19:09:27 +05'30'

Nand Kishor Ray
Additional Director
DIN: 11626638

Date: 13-08-2026
Place: Gujrat